# Study of NT-501 Encapsulated Cell Therapy for Glaucoma Neuroprotection and Vision Restoration

> **NCT02862938** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Stanford University** · enrollment: 54 (actual)

## Conditions studied

- Glaucoma

## Interventions

- **DRUG:** NT-501 ECT implant
- **OTHER:** Sham

## Key facts

- **NCT ID:** NCT02862938
- **Lead sponsor:** Stanford University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2016-06
- **Primary completion:** 2025-08-15
- **Final completion:** 2026-08-15
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2025-11-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02862938

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02862938, "Study of NT-501 Encapsulated Cell Therapy for Glaucoma Neuroprotection and Vision Restoration". Retrieved via AI Analytics 2026-08-03 from https://api.ai-analytics.org/clinical/NCT02862938. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*